

Japan Biotech Forum: London 2009

Licensing and investment opportunities emerging from Japan

Thursday 10 September 2009

The Royal Society, 6-9 Carlton House Terrace, London SW1Y 5AG

Programme

- | | |
|-------|---|
| 09:30 | Registration with tea and coffee |
| 10:00 | Welcome
Dr Chizuko Koseki, Representative Director, transB Ltd. |
| 10:05 | Overview of the current Japanese biotech industry and investment outlook
Mr Hiroki Narita, Daiwa SMBC Capital Co. Ltd. |
| 10:10 | Presentations from Japanese biotech companies (see overleaf) |
| 12:00 | LUNCH |
| 13:00 | Presentations from Japanese biotech companies continued |
| 14:00 | One-to-one partnering with selected companies |
| 16:30 | Closing remarks |

Sponsors and supporters

BioCentury[®]JAL
JAPAN AIRLINESPHARMA TELEVISIONKendle
Real people. Real results.[®]InCROM

THOMSON REUTERS

To register, contact Maki Aoyama at m.aoyama@transb.co.uk

www.transb.co.uk/japan_biotech_forum_2009.htm

Invited speakers from Japan

transB has specially selected a handful of innovative Japanese biotech companies to present at this Forum. Products listed here are a partial list from their portfolio and more products may be presented.

Clinical stage biopharmaceutical companies

Sosei Group (*MOTHERS index: 4565*) Late clinical stage biopharmaceutical company

SD118: Oral small molecule for neuropathic pain; Phase I completed

AD337/SD726: Fibromyalgia; Phase IIa completed

DRP049: Liver and kidney fibrosis; Preclinical

SD208/281: Orally active small molecule for psoriasis; Preclinical

MebioPharm *DDS applied oncology focus company*

MBP-426: Transferrin-conjugated nano particle formulation of oxaliplatin for colon cancer; Phase I completed

RaQualia *Spin-out from Pfizer*

RQ-007 & RQ-008: First-in-class EP4 receptor antagonists for Pain, Inflammation & Cancer; Phase IIa & Preclinical

RQ-009: Dual action CNS-penetrating oral small molecule for Alzheimer's disease; Phase I completed

aRigen Pharmaceuticals *Novel drugs for infectious diseases*

WAP-8294A2: First-line therapy for MRSA infection in topical and injectable formulations; Phase I

GNI (*MOTHERS index: 2160*) *Clinical-stage biopharmaceutical company focusing on major diseases prevalent in Asia*

F-647: Oral small molecule Pirfenidone (F647) for idiopathic pulmonary fibrosis; Phase II

F-351: Oral small molecule therapy for liver fibrosis; Phase I

Cutting edge platform technology companies

ReproCELL *In vitro cardio-toxicity measurement using beating cardiomyocytes derived from iPS and embryonic stem cells*

alphaGEN *Chimera siRNA/DNA technology with benefits over siRNA*

Benefits of attending

- Presentations from senior representatives from Japanese biotech companies
- Corporate and product analyses provided as handouts
- One-to-one partnering opportunity
- Networking with delegates from the licensing and investment communities

Registration

Standard delegate rate: £200 + VAT (total £230)

Second delegate from the same organisation: £100 + VAT (total £115)

Please note: Attendance will be confirmed upon receipt of payment. Prices include all refreshments and delegate documentation.

Attendance is by INVITATION ONLY to ensure that the quality of interactions is maintained. To apply for an invitation or to register,

please contact Maki Aoyama at m.aoyama@transb.co.uk. Cancellations must be made at least 7 days prior to the event for

refunds to be made (minus a 10% administration charge). No refunds will be made after 3 September.

How to get there

Venue: The Royal Society (www.royalsociety.org), 6-9 Carlton House Terrace, London SW1Y 5AG.



Underground

The nearest underground stations are Charing Cross (Bakerloo and Northern lines) and Piccadilly Circus (Bakerloo and Piccadilly lines).

Car

There are no car parking facilities at the Society, however there are metered bays within a short walk.

©2009 Google – Map data ©2009 Tele Atlas

A consulting firm with a focus on the Japanese biotech and pharmaceutical sectors

transB's vision is to provide clients with the best insights and analyses of cutting edge science, products and business opportunities to enable informed decisions that lead to successful cross-border transactions. The role of transB is to act as a powerful catalyst that bridges the gap between Japanese biotech communities and the global stage. For more information, contact Chizuko Koseki at c.koseki@transb.co.uk.

To register, contact Maki Aoyama at m.aoyama@transb.co.uk

www.transb.co.uk/japan_biotech_forum_2009.htm